idarubicin has been researched along with dactinomycin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M | 1 |
| Beske, F; Boos, J; Dantonello, T; Gadner, H; Hallmen, E; Int-Veen, C; Kazanowska, B; Klingebiel, T; Koscielniak, E; Marky, I; Treuner, J | 1 |
1 review(s) available for idarubicin and dactinomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for idarubicin and dactinomycin
| Article | Year |
|---|---|
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Epirubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Kaplan-Meier Estimate; Male; Melphalan; Sarcoma; Soft Tissue Neoplasms; Thiotepa; Treatment Outcome; Vincristine | 2008 |
2 other study(ies) available for idarubicin and dactinomycin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoiesis; Humans; Idarubicin; Ifosfamide; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2004 |